IP Library Granted Patent US 9,150,880
Granted Patent B2
US 9,150,880 · App. 12/567,334 · Granted Oct 6, 2015

Vectors for production of antibodies

Inventors: Richard K. Cooper (Baton Rouge, LA); William C. Fioretti (Addison, TX)
Assignee: PROTEOVEC HOLDING, L.L.C.
C12N15/8509C07K16/00C07K16/3076A01K2267/01C07K2317/21C07K2317/23C12N2800/107C12N2800/90
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,150,880
App. No.
12/567,334
Granted
Oct 6, 2015
Kind
B2
Abstract

Novel compositions for the production of the light and heavy chains of an antibody are provided. These novel compositions are also used to produce germline transgenic birds that can successfully pass the transgene encoding the antibody to their offspring. The compositions comprise components of vectors, such as a vector backbone, a promoter, and a gene of interest that encodes the light or heavy chain of an antibody, and the vectors comprising these components. In certain embodiments, these vectors are transposon-based vectors. Also provided are methods of making these compositions and methods of using these compositions for the production of the light and heavy chains of an antibody. In one embodiment, the antibody is a human monoclonal antibody.

Claims (24)

1. A vector comprising:

a modified transposase gene operably linked to a first promoter, wherein the nucleotide sequence 3′ to the first promoter comprises a modified Kozak sequence, and wherein a plurality of the first twenty codons of the transposase gene are modified from the wild-type sequence by changing the nucleotide at the third base position of the codon to an adenine or thymine without modifying the amino acid encoded by the codon;

a multiple cloning site capable of receiving a gene of interest;

transposon insertion sequences recognized by a transposase encoded by the modified transposase gene, wherein the transposon insertion sequences flank the multiple cloning site; and,

one or more insulator elements located between the transposon insertion sequences and the multiple cloning site, wherein the one or more insulator elements comprise a lysozyme replicator element, a combination of a lysozyme replicator element and an HS4 element, or a matrix attachment region element, wherein when the gene of interest is inserted into the multiple cloning site, the start codon of the gene of interest is located no more than 2502 bp and no less than 1652 bp from the one or more insulator elements located 5′ to the start codon of the gene of interest.

2. The vector of claim 1 , further comprising a second promoter, wherein the second promoter is SEQ ID NO: 14 or SEQ ID NO: 15.

3. The vector of claim 1 , further comprising a gene encoding for an antibody inserted into the multiple cloning site.

4. The vector of claim 3 , wherein the vector comprises SEQ ID NO: 25.

5. A transposon-based vector comprising:

a modified transposase gene operably linked to a first promoter, wherein the nucleotide sequence 3′ to the first promoter comprises a modified Kozak sequence, and wherein a plurality of the first twenty codons of the transposase gene are modified from the wild-type sequence by changing the nucleotide at the third base position of the codon to an adenine or thymine without modifying the amino acid encoded by the codon;

one or more genes of interest encoding an antibody operably-linked to one or more additional promoters, wherein the one or more genes of interest encoding the antibody and their operably-linked promoters are flanked by transposon insertion sequences recognized by a transposase encoded by the modified transposase gene; and,

one or more insulator elements located between the transposon insertion sequences and the one or more genes of interest encoding the antibody, wherein the start codon of the gene of interest is located about 2502 bp to about 1652 bp from the one or more insulator elements located 5′ to the start codon of the gene of interest, and wherein the one or more insulator elements comprise a lysozyme replicator element, a combination of a lysozyme replicator element and an HS4 element, or a matrix attachment region element.

6. A method of producing an antibody comprising:

transfecting a cell with a vector comprising

a modified transposase gene operably linked to a first promoter, wherein the nucleotide sequence 3′ to the first promoter comprises a modified Kozak sequence, and wherein a plurality of the first twenty codons of the transposase gene are modified from the wild-type sequence by changing the nucleotide at the third base position of the codon to an adenine or thymine without modifying the amino acid encoded by the codon;

one or more genes of interest encoding an antibody operably-linked to one or more additional promoters, wherein the one or more genes of interest encoding the antibody and their operably-linked promoters are flanked by transposon insertion sequences recognized by a transposase encoded by the modified transposase gene; and,

one or more insulator elements located between the transposon insertion sequences and the one or more genes of interest encoding the antibody, wherein the start codon of the gene of interest is located about 2502 bp to about 1652 bp from the one or more insulator elements located 5′ to the start codon of the gene of interest, and wherein the one or more insulator elements comprise a lysozyme replicator element, a combination of a lysozyme replicator element and an HS4 element, or a matrix attachment region element;

culturing the transfected cell in culture medium;

permitting the cell to release the antibody into the culture medium;

collecting the culture medium; and,

isolating the antibody.

7. The method of claim 6 wherein the vector comprises SEQ ID NO:25.

8. The method of claim 6 wherein the antibody is a human antibody.

9. The method of claim 6 wherein the antibody is a monoclonal antibody.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 5, 2015
From: THE BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE
To: PROTEOVEC HOLDING, L.L.C.
Reel/Frame 035566/0906 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 5, 2015
From: TRANSGENRX, INC.
To: PROTEOVEC HOLDING, L.L.C.
Reel/Frame 035566/0931 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 23, 2009
From: FIORETTI, WILLIAM C.
To: TRANSGENRX, INC.
Reel/Frame 023415/0819 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 23, 2009
From: COOPER, RICHARD K.
To: THE BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE
Reel/Frame 023415/0942 →
Continuity (3)
Provisional Application 61231555 · Aug 5, 2009
Provisional Application 61100075 · Sep 25, 2008
Related Publication 20100099148A1 · Apr 22, 2010